Loading...
•
Sep 30, 2024
Enliven Therapeutics Q3 2024 Earnings Report
Reported third quarter financial results and provided a business update, highlighting pipeline progress.
Key Takeaways
Enliven Therapeutics reported its third quarter financial results, highlighting positive data from the Phase 1 clinical trial of ELVN-001 and continued progress with ELVN-002. The company's cash position remains strong with $291.8 million, expected to provide runway into late 2026.
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks.
ELVN-001 remains well-tolerated with no dose reductions.
Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC.
Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Enliven plans to report additional Phase 1 data in 2025 for ELVN-001 and ELVN-002.